Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.

IF 5.4 2区医学 Q1 IMMUNOLOGY

BioDrugs Pub Date : 2023-07-01 DOI:10.1007/s40259-023-00606-5

Avani M Singh, Jose A Guevara-Patino, Xuefeng Wang, Roger Li, Guru Sonpavde, Rohit K Jain

引用次数: 0

Abstract

Antibody-drug conjugates (ADCs) have transformed the treatment landscape in oncology and become an essential therapeutic modality. In urothelial carcinoma (UC), the two ADCs that have been especially successful in clinical practice are enfortumab vedotin and sacituzumab govitecan. These drugs are currently approved as monotherapy for later lines of treatment in locally advanced or metastatic UC and have had a significant impact for patients with limited treatment options. Combinational trials, as well as additional ADCs, are currently being investigated in the treatment of UC for subsequent lines of therapy as overall survival rates remain dismal.

Abstract Image

查看原文本刊更多论文

抗体-药物偶联物治疗尿路上皮癌。

抗体-药物偶联物(adc)已经改变了肿瘤治疗的格局，成为一种基本的治疗方式。在尿路上皮癌(UC)中，在临床实践中特别成功的两种adc是enfortumab vedotin和sacituzumab govitecan。这些药物目前被批准作为局部晚期或转移性UC的后期治疗的单一疗法，并对治疗选择有限的患者产生了重大影响。由于总生存率仍然很低，目前正在研究UC治疗的联合试验以及额外的adc。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BioDrugs 医学-免疫学

CiteScore

12.60

自引率

2.90%

发文量

审稿时长

>12 weeks

期刊介绍： An essential resource for R&D professionals and clinicians with an interest in biologic therapies. BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.